For the readers interested in the stock health of Xeris Biopharma Holdings Inc. (XERS). It is currently valued at $1.30. When the transactions were called off in the previous session, Stock hit the highs of $1.36, after setting-off with the price of $1.26. Company’s stock value dipped to $1.24 during the trading on the day. When the trading was stopped its value was $1.21.Recently in News on March 8, 2023, Xeris Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides 2023 Financial Guidance. Achieved fourth quarter net product revenue of $32.5M representing 52% growth compared to Q4 2021. You can read further details here
Xeris Biopharma Holdings Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.9500 on 03/18/22, with the lowest value was $0.9701 for the same time period, recorded on 01/05/23.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Xeris Biopharma Holdings Inc. (XERS) full year performance was -51.85%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Xeris Biopharma Holdings Inc. shares are logging -55.93% during the 52-week period from high price, and 34.01% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.97 and $2.95.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1218326 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Xeris Biopharma Holdings Inc. (XERS) recorded performance in the market was -2.26%, having the revenues showcasing -10.34% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 182.65M, as it employees total of 355 workers.
Xeris Biopharma Holdings Inc. (XERS) in the eye of market guru’s
During the last month, 0 analysts gave the Xeris Biopharma Holdings Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.3202, with a change in the price was noted unch. In a similar fashion, Xeris Biopharma Holdings Inc. posted a movement of unch for the period of last 100 days, recording 927,827 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for XERS is recording 4.14 at the time of this writing. In addition, long term Debt to Equity ratio is set at 4.14.
Xeris Biopharma Holdings Inc. (XERS): Stocks Technical analysis and Trends
Raw Stochastic average of Xeris Biopharma Holdings Inc. in the period of last 50 days is set at 55.92%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 39.53%. In the last 20 days, the company’s Stochastic %K was 27.40% and its Stochastic %D was recorded 29.19%.
If we look into the earlier routines of Xeris Biopharma Holdings Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -2.26%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -28.96%, alongside a downfall of -51.85% for the period of the last 12 months. The shares increased approximately by -15.03% in the 7-day charts and went down by 14.04% in the period of the last 30 days. Common stock shares were lifted by -10.34% during last recorded quarter.
